Upgrade to SI Premium - Free Trial

BioLineRx (BLRX)

2.93 +0.07 (2.45%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/14/26 *Est.)

Latest Headlines

BioLineRx and Hemispherian to present GLIX1 ovarian cancer data at ESMO July 20, 2026 7:02 AM - StreetInsider BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 July 20, 2026 7:00 AM - PR NewsWire Form 6-K BioLineRx Ltd. For: Jul 08 July 8, 2026 7:08 AM - SEC Filing BioLineRx and Hemispherian report GLIX1 and olaparib synergy in ovarian cancer July 8, 2026 7:00 AM - StreetInsider BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model July 8, 2026 7:00 AM - PR NewsWire BioLineRx (BLRX) Reports In-Line Q1 EPS May 27, 2026 7:38 AM - StreetInsider Form 6-K BioLineRx Ltd. For: May 27 May 27, 2026 7:20 AM - SEC Filing BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update May 27, 2026 7:00 AM - PR NewsWire BioLineRx and Hemispherian to present GLIX1 data at ASCO 2026 May 22, 2026 7:01 AM - StreetInsider Form 6-K BioLineRx Ltd. For: May 22 May 22, 2026 7:00 AM - SEC Filing BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting May 22, 2026 7:00 AM - PR NewsWire BioLineRx to Report First Quarter 2026 Results on May 27, 2026 May 20, 2026 7:01 AM - PR NewsWire Form 6-K BioLineRx Ltd. For: May 19 May 19, 2026 7:07 AM - SEC Filing BioLineRx reports positive preclinical data for GLIX1 in brain cancer May 19, 2026 7:02 AM - StreetInsider BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat May 19, 2026 7:00 AM - PR NewsWire Form 6-K BioLineRx Ltd. For: Apr 28 April 28, 2026 7:16 AM - SEC Filing BioLineRx doses first patient in glioblastoma trial with GLIX1 drug April 28, 2026 7:00 AM - StreetInsider BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) April 28, 2026 7:00 AM - PR NewsWire Full Article List